Syros Pharmaceuticals Q3 2024 GAAP EPS $(0.16) Beats $(0.72) Estimate. Cash and Equivalents Of $60.4M
Portfolio Pulse from Benzinga Newsdesk
Syros Pharmaceuticals reported a Q3 2024 GAAP EPS of $(0.16), significantly beating the analyst estimate of $(0.72). This marks an 88.81% improvement from the previous year's loss of $(1.43) per share. The company holds $60.4M in cash and equivalents.
October 31, 2024 | 10:55 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Syros Pharmaceuticals' Q3 2024 earnings per share of $(0.16) exceeded expectations, showing a significant improvement from last year. The company also maintains a strong cash position.
The better-than-expected earnings per share and significant year-over-year improvement are likely to positively impact Syros Pharmaceuticals' stock price in the short term. The strong cash position further supports financial stability.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100